Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

SEXUAL HEALTHInvestigational

Melanotan II

Melanocyte Stimulator · 10mg

Status

Investigational

Route

SubQ

Half-life

~33 hours plasma

Class

Melanocortin agonist

MechanismMC1R Activation

Cohort12 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$70 USD/vial

À-la-carte: $75 USD/vial · Save 7%

Vials per allocation

Member total (1×)$70

À-la-carte total$75

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Melanocortin receptor agonist used in specific photoprotection and pigmentation research protocols.

Melanocyte Stimulator · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Melanotan II · Sexual health

◆ Certificate of Analysis · Melanotan II

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Lot-specific COAs for Melanotan II are published with each batch release. Sample certificates available on request via partnerships@vivrelabs.com.

◉

Clinical Overview

Melanotan II

Melanotan II is a 7-amino-acid synthetic analog of alpha-melanocyte-stimulating hormone. Originally developed as a sunless tanning research compound.

Activates multiple melanocortin receptors with broader effects than the parent peptide.

✦

Melanocortin Agonism

Activates MC1R and other melanocortin receptors.

◈

Broad Receptor Activity

MC3/4/5R activity contributes to intended and off-target effects.

❖

Caution

Broad activity warrants careful physician oversight.

◈

Mechanism

How It Works

Activates MC1R (melanin production), MC3R, MC4R (appetite, sexual function), and MC5R receptors. The broad receptor activity contributes to both intended and unintended effects.

Mechanism & evidence - the honest frame

Mechanism & evidence - honest tier: Melanotan II is a synthetic cyclic alpha-MSH analogue and a NON-selective melanocortin-receptor agonist (MC1R drives the pigmentation; off-target MC3R/MC4R drive the nausea, flushing, appetite suppression and erections seen in the original Dorr 1996 pilot). It is NOT approved for any indication by any major regulator and is illegal to sell for human use in many markets. The melanoma question is unresolved: at least five melanomas have been reported in users, but all had other risk factors (fair skin, tanning beds, family history) and causation is unproven (a 2013 review found no conclusive causal evidence; a 2021 review attributed the excess risk to UV-seeking behaviour) - however mole darkening and proliferation of atypical naevi are well documented and may not fully reverse. Vivre’s position: this is a dermatology-supervised compound, contraindicated with personal/family melanoma history or atypical-mole syndrome, requiring baseline and follow-up mole mapping; it is never presented as a risk-free cosmetic.

⊞

Technical Profile

Measurable Properties

Class	Non-selective melanocortin-receptor agonist
Mechanism	MC1R/MC4R agonism; melanogenesis and other melanocortin effects
Terminal half-life	Short (order of an hour+); non-selective receptor activity
Metabolism	Peptidase degradation
Evidence base	Limited controlled human data; notable safety/side-effect concerns documented
Regulatory status	Not an approved therapy; significant safety caution; physician-supervised use only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Non-selective activity and documented safety concerns - stated explicitly, not minimised. Educational only.

Clinical Literature

Peer-Reviewed References

An overview of benefits and risks of chronic melanocortin-1 receptor activation

Review (melanocortin pharmacology) · 2024 · PMC11664455

▾

Findings

Melanotan II is a synthetic cyclic alpha-MSH analogue and NON-selective melanocortin receptor (MC1R/MC3R/MC4R) agonist; not approved for any therapeutic indication. At least five melanomas have been reported during/after MT-II use - but all individuals had other risk factors (fair skin, tanning-bed use, family history); causation is unproven. Mole darkening and proliferation of atypical naevi are documented and may not fully reverse.

View on publisher ↗

Evaluation of melanotan II, a superpotent cyclic melanotropic peptide in a pilot phase-1 clinical study

Dorr RT, Lines R, Levine N, et al. · 1996 · Life Sciences 1996;58(20):1777–1784

▾

Findings

Early human pilot establishing MT-II tanning activity and its off-target profile: the non-selective MC3R/MC4R activation drives nausea, spontaneous erections, appetite suppression, flushing and yawning - the side-effect cluster that halted its development as a cosmetic tanning agent.

View on publisher ↗

Honest tier: real mechanism, but the LEAST-regulated, least-studied compound in this space - no regulatory approval anywhere, illegal to sell for human use in many markets, and a consistent (if unproven) melanoma signal. Vivre treats it as a dermatology-supervised compound requiring baseline and follow-up mole mapping; contraindicated with personal/family melanoma history or atypical-mole syndrome. Never framed as performance or risk-free cosmetic.

◇

Clinical Applications

Indications

Photoprotection research
Pigmentation disorders (research-grade)
Specialized cases under close physician oversight

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~33 hours plasma. Notably longer than most peptides in this catalogue; this longer half-life is part of the risk profile that requires individual physician case review before allocation.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Research-grade. Clinical use is specialized and limited. Risk profile requires physician oversight.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

READY TO PROCEED

Start with the Biological Audit

Melanotan II is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$70 USD/vial

Melanotan II · Member rate